Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, announced it has launched Tranexamic Acid in 0.7% Sodium Chloride Injection in the United States. The product contains the same active ingredient as...
Women's health supplement brand Ritual in partnership with Brooklyn College (CUNY) announced the publication of the folate results from their clinical trial on their top-selling Essential Prenatal in the journal Frontiers in Nutrition. The...
Viralgen, a leading contract development and manufacturing organization (CDMO) specializing in recombinant adeno-associated virus (rAAV) gene therapies, announced today a partnership with Elaaj Bio, a biotechnology company focused on development...
Amazon Pharmacy a full-service digital pharmacy that delivers medications directly to customers' homes, is expanding access to Novo Nordisk's Ozempic® pill, the only FDA-approved oral GLP-1 medication to treat type 2 diabetes. Amazon Pharmacy will...
Joi + Blokes, a telehealth platform specializing in diagnostic testing, personalized medicine, and hormone and menopause care, announced the publication of a new peer-reviewed study demonstrating that testosterone replacement therapy (TRT) in...
BioOra Limited, a New Zealand-based company pioneering automated, cost-effective CAR T-cell manufacturing, announced the signing of a binding Heads of Terms agreement with Wellingto. Zhaotai Therapies Limited (Wellington Zhaotai) under which...
NurtureBio, a new maternal and child wellness company focused on emerging scientific solutions to gut health issues, today announced its official launch and the release of its first product: a synbiotic supplement. This synbiotic features human...
InFocus Clinical Research, the only global, full-service retina specialty contract research organization, announced that Elizabeth Nanouris has joined InFocus as vice president of business operations. Nanouris joins a robust operations team and...
TruLeaf Medical, Ltd, a fully-owned subsidiary of Allmed Solutions (TASE: ALMD), a clinical-stage medical device company specializing in transcatheter structural heart innovations, is pleased to announce the successful completion of the full...
Novo Nordisk announced that starting Monday, May 4, Ozempic® (semaglutide) tablets 1.5 mg, 4 mg, and 9 mg will be available for adults with type 2 diabetes in the US. Ozempic® is the only FDA-approved oral peptide GLP-1 medication for adults with...
Incyte announced that the U.S. Food and Drug Administration (FDA) has approved Jakafi XR™ (ruxolitinib) extended-release tablets for the treatment of adults with intermediate- or high-risk myelofibrosis (MF); adults with polycythemia vera (PV) who...
UCB, a global biopharmaceutical company, announced signing of a definitive agreement under which it would acquire Candid Therapeutics (Candid), a privately held clinical-stage biotechnology company redefining the treatment of autoimmune and...
TIME has named Sprout Pharmaceuticals among just 10 organizations globally shaping the future of health and life sciences. This recognition follows a defining period of momentum for Sprout and its flagship treatment, Addyi. In December 2025, the...
YARAL Pharma Inc. the rapidly growing U.S. generics subsidiary of IBSA (Institut Biochimique SA), announced that its Diclofenac Epolamine Topical System 1.3%, the authorized generic of Flector® (diclofenac epolamine) topical system 1.3%, is now...
SQ Innovation, developer of Lasix® ONYU, announced two important regulatory milestones in its international expansion strategy: the receipt of a CE marking certificate for the Lasix ONYU device, and the acceptance of Lasix ONYU by the European...
Rapid Nexus Nanotech Wound Solutions, Inc., a California-based medical technology company, announced it has secured supply contracts with the U.S. Department of Veterans Affairs (VA) and Department of Defense (DoD) and will begin commercial...
Apertura Gene Therapy, a biotechnology company developing next-generation AAV capsids for delivering genetic medicines, along with scientists from the Broad Institute of MIT and Harvard, will present advancements related to TfR1 CapX™. A leading...
AbbVie announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval for SKYRIZI® (risankizumab-rzaa) for subcutaneous (SC) induction for the treatment of adult patients with moderately to severely...
Mundipharma announced positive Phase III topline results from the global ReSPECT clinical trial evaluating REZZAYO® (rezafungin acetate) for prophylaxis of invasive fungal diseases (IFDs) in adult patients undergoing allogeneic haematopoietic stem...
Cellenkos®, Inc., a clinical-stage biotechnology company, developing allogeneic, tissue-targeted regulatory T cell (Treg) therapies, today announced the receipt of U.S. Food and Drug Administration (FDA) clearance to initiate CK0801 Phase 2...
